Skip to main content

PSMA Targeted Imaging and Therapy: Prostate and Other Cancers

  1. Detection of the site of recurrence using PSMA-PET/CT is important to guide treatment in patients with biochemical recurrence of prostate cancer (PCa). The aim of this study was to evaluate the positivity rate...

    Authors: Niloefar Ahmadi Bidakhvidi, Annouschka Laenen, Sander Jentjens, Christophe M. Deroose, Koen Van Laere, Liesbeth De Wever, Cindy Mai, Charlien Berghen, Gert De Meerleer, Karin Haustermans, Steven Joniau, Wouter Everaerts and Karolien Goffin
    Citation: EJNMMI Research 2021 11:41
  2. Intraoperative identification of prostate cancer (PCa) lymph node (LN) metastases (LNM) detected by preoperative PSMA PET/CT may be facilitated by PSMA radio-guided surgery (RGS) with use of a γ-probe. Earlier...

    Authors: Michael Mix, Wolfgang Schultze-Seemann, Moritz von Büren, August Sigle, Mohamed A. Omrane, Markus T. Grabbert, Martin Werner, Christian Gratzke, Philipp T. Meyer and Cordula A. Jilg
    Citation: EJNMMI Research 2021 11:22
  3. [68Ga]Ga-PSMA-11 PET/CT allows for a superior detection of prostate cancer tissue, especially in the context of a low tumor burden. Digital PET/CT bears the potential of reducing scan time duration/administered t...

    Authors: Manuel Weber, Walter Jentzen, Regina Hofferber, Ken Herrmann, Wolfgang Peter Fendler, Maurizio Conti, Axel Wetter, David Kersting, Christoph Rischpler and Pedro Fragoso Costa
    Citation: EJNMMI Research 2021 11:21
  4. Until now, results evaluating the expression of PSMA in ovarian cancer were sparse and contradictory. The aim was to reinvestigate the feasibility of a PSMA targeted theranostic approach in epithelial ovarian ...

    Authors: Nicolas Aide, Laurent Poulain, Nicolas Elie, Mélanie Briand, Florence Giffard, Cécile Blanc-Fournier, Florence Joly and Charline Lasnon
    Citation: EJNMMI Research 2021 11:11
  5. Clinical management decisions on prostate cancer (PCa) are often based on a determination of risk. 68Ga-prostate-specific membrane antigen (PSMA)-11-positron emission tomography (PET)/computer tomography (CT) is ...

    Authors: Jun-jie Hong, Bo-le Liu, Zhi-qiang Wang, Kun Tang, Xiao-wei Ji, Wei-wei Yin, Jie Lin and Xiang-wu Zheng
    Citation: EJNMMI Research 2020 10:138
  6. Brain metastases from prostate cancer are rare and usually only occur in the context of widespread systemic disease. This is the first case report of a solitary brain oligometastasis, in a neurologically intac...

    Authors: M. I. Ross, N. Bird, I. A. Mendichovszky and Y. L. Rimmer
    Citation: EJNMMI Research 2020 10:108

    The Correction to this article has been published in EJNMMI Research 2020 10:129

  7. Focal therapies or focally escalated therapies of primary prostate cancer are becoming more and more important. This increases the need to identify the exact extension of the intraprostatic tumor and possible ...

    Authors: Thomas Franz Fassbender, Florian Schiller, Constantinos Zamboglou, Vanessa Drendel, Selina Kiefer, Cordula A. Jilg, Anca-Ligia Grosu and Michael Mix
    Citation: EJNMMI Research 2020 10:62
  8. To investigate the added value and diagnostic accuracy of 68Ga-PSMA PET/CT versus bone scintigraphy (BS) for bone metastasis detection at the primary staging of prostate cancer (PCa).

    Authors: Helle D. Zacho, Søren Ravn, Ali Afshar-Oromieh, Joan Fledelius, June A. Ejlersen and Lars J. Petersen
    Citation: EJNMMI Research 2020 10:31
  9. Differentiated thyroid carcinoma (DTC) is the most common type of thyroid cancer. Treatment with surgery, radioactive iodine (RAI), and TSH suppression is effective in most patients. Five to 15% of patients be...

    Authors: Lisa H. de Vries, Lutske Lodewijk, Arthur J. A. T. Braat, Gerard C. Krijger, Gerlof D. Valk, Marnix G. E. H. Lam, Inne H. M. Borel Rinkes, Menno R. Vriens and Bart de Keizer
    Citation: EJNMMI Research 2020 10:18
  10. Identification of suspicious PSMA-PET/CT-positive lymph node (LN) metastases (LNM) from prostate cancer (PCa) during lymphadenectomy (LA) is challenging. We evaluated an 111In-labelled PSMA ligand (DKFZ-617, refe...

    Authors: Cordula A. Jilg, Kathrin Reichel, Christian Stoykow, H. Christian Rischke, Mark Bartholomä, Vanessa Drendel, Moritz von Büren, Wolfgang Schultze-Seemann, Philipp T. Meyer and Michael Mix
    Citation: EJNMMI Research 2020 10:17
  11. Prostate-specific membrane antigen (PSMA) ligand PET/CT has already provided promising results in prostate cancer (PC) imaging, yet simple and reproductible reporting criteria are still lacking. This study aim...

    Authors: Céline Derwael, Olivier Lavergne, Pierre Lovinfosse, Vlad Nechifor, Mallory Salvé, David Waltregny, Roland Hustinx and Nadia Withofs
    Citation: EJNMMI Research 2020 10:15
  12. Several scan parameters for PET imaging with 18F-PSMA-11 such as dosage, acquisition time and scan duration were evaluated to determine the most appropriate scan protocol, as well as the effect of furosemide admi...

    Authors: Sarah Piron, Kathia De Man, Vanessa Schelfhout, Nick Van Laeken, Ken Kersemans, Eric Achten, Filip De Vos and Piet Ost
    Citation: EJNMMI Research 2020 10:14
  13. The positron emission tomography (PET) ligand 68Ga-Glu-urea-Lys(Ahx)-HBED-CC (68Ga-PSMA-11) targets the prostate-specific membrane antigen (PSMA), upregulated in prostate cancer cells. Although 68Ga-PSMA-11 PET i...

    Authors: Anna Ringheim, Guilherme de Carvalho Campos Neto, Udunna Anazodo, Lumeng Cui, Marcelo Livorsi da Cunha, Taise Vitor, Karine Minaif Martins, Ana Cláudia Camargo Miranda, Marycel Figols de Barboza, Leonardo Lima Fuscaldi, Gustavo Caserta Lemos, José Roberto Colombo Junior and Ronaldo Hueb Baroni
    Citation: EJNMMI Research 2020 10:12